Skip to main content

Table 5 Effect of NOMAC on osteodensitometry (DEXA) measurements of L1 to L5 of the lumbar rachis

From: Preclinical pharmacological profile of nomegestrol acetate, a synthetic 19-nor-progesterone derivative

Treatment DEXA measurements (%)
Day 20 Day 41 Day 62 Day 90
Intact control 104.8 ± 1.4 105.5 ± 2.5 105.9 ± 1.5 108.0 ± 1.4
% treatment of intact control 100 100 100 100
OVX control 94.4 ± 2.3 95.5 ± 1.7 97.0 ± 2.8 95.1 ± 2.7
% treatment of intact control −9.9 −9.4 −8.4 −12
E2 (1 μg/kg/day) 98.2 ± 0.7 100.8 ± 1.4 103.6 ± 1.7 102.8 ± 1.8
% treatment of OVX control +4.0 +5.5 +6.8* +8.1**
NOMAC (1 mg/kg/day) 92.7 ± 0.8 93.4 ± 0.5 92.2 ± 1.1 93.2 ± 2.3
% treatment of OVX control −1.8 −2.3 −4.9 −2.0
E2 (1 μg/kg/day) + NOMAC (1 mg/kg/day) 98.7 ± 1.1 97.5 ± 1.9 102.0 ± 1.0 101.5 ± 1.1
% treatment of OVX control +4.6* +2.1 +5.2* +6.7*
  1. ANOVA, analysis of variance; DEXA, dual-energy X-ray absorptiometry; E2, 17β-estradiol; NOMAC, nomegestrol acetate; OVX, ovariectomized. Data are percentages of DEXA values and are expressed as the mean ± standard error of the mean. * P<0.05; ** P<0.01 compared with OVX control animals (ANOVA).
  2. At 3-week intervals, osteodensitometry measurements of the lumbar vertebrae (L1 to L6) were made using DEXA. After 90 days, the animals were sacrificed, the femur and L5 vertebra removed, and dynamic osteodensitometric measurements were made.